Chemokines and their receptors play critical roles in the progression of autoimmunity and inflammation and cancer. Typically, multiple chemokines are involved in the development of these pathologies. Indeed, targeting single chemokines or chemokine receptors has failed to achieve significant clinical benefits in treating autoimmunity and inflammation. In our work, promiscuous chemokine binding peptides that could bind and inhibit multiple inflammatory chemokines, such as CCL20, CCL2, CCL5, and CXCL9/10/11, were selected from phage display libraries. These peptides were cloned into human mutated immunoglobulin Fc-protein fusions (peptibodies). These peptibodies showed a significant inhibition of disease progression in a variety of animal models for autoimmunity, inflammation and cancer. Based on our peptibodies we develop HTP screening system which allow us the identification of novel anti chemokines small molecules.
